B-PaLMZ for TB meningitis in people with HIV
Part of Brain & nervous system, Infections clinical trials.
This trial tests a combination of TB medicines (B-PaLMZ) for people with HIV who have their first episode of TB meningitis. It aims to find a better treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are living with HIV
- You are being diagnosed with your first episode of TB meningitis and your doctor plans to treat it
- You weigh more than 35 kg (about 77 pounds)
- You have not taken more than 5 doses of any TB medicine in the last 14 days
- You do not have a known TB that is resistant to rifampicin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an intensified, shorter treatment plan for TB meningitis (TB in the lining around the brain) in adults, including people with HIV. It may help some patients get better with a structured plan while researchers compare treatment outcomes and safety.
This trial tests if giving a stronger combination of TB drugs for meningitis can save more lives. It's for patients who have been diagnosed with tuberculosis meningitis and have not yet started more than 5 days of TB treatment.
This Phase 2 study tests whether a shorter, stronger 6-month set of medicines works as well as the usual 9-month regimen for tuberculous meningitis (TB infection in the covering of the brain/spinal cord). The goal is to improve outcomes while reducing treatment time and exposure.
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
This trial tests a new antibiotic called contezolid for people with tuberculous meningitis, an infection of the brain lining. The goal is to see if it works well and is safe.
This trial studies a specific drug combination (BPaLM) for adults with drug-resistant pulmonary (lung) tuberculosis. If you qualify, the goal is to see whether this treatment is effective and safe for your type of infection.
Hear when a new Tuberculous Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.